Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Theseus Pharmaceuticals, Inc. (THRX : NSDQ)

• Company Description    Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $8.88 Daily Weekly Monthly 20 Day Moving Average: 116,664 shares Shares Outstanding: 43.56 (millions) Market Capitalization: $386.82 (millions) Beta: 4.25 52 Week High: $14.77 52 Week Low: $4.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.99% -5.04% 12 Week 11.14% 2.99% Year To Date 78.31% 46.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 314 MAIN STREET - CAMBRIDGE,MA 02142 USA ph: 857-400-9491 fax: - josh.rappaport@sternir.com http://www.theseusrx.com

• General Corporate Information    Officers Timothy Clackson - President; Chief Executive Officer and Director Iain D. Dukes - Chairman and Director Bradford Dahms - Chief Financial Officer Carl L. Gordon - Director Donald J. Hayden - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 88369M101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/22 Next Expected EPS Date: 05/11/23 Share - Related Items Shares Outstanding: 43.56 Most Recent Split Date: (:1) Beta: 4.25 Market Capitalization: $386.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.74 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/11/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.66 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -45.83% vs. Previous Quarter: 7.89% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -22.67 12/31/22 - -19.55 09/30/22 - -23.03 ROA 03/31/23 - -21.57 12/31/22 - -18.84 09/30/22 - -18.30 Current Ratio 03/31/23 - 18.16 12/31/22 - 27.54 09/30/22 - 43.66 Quick Ratio 03/31/23 - 18.16 12/31/22 - 27.54 09/30/22 - 43.66 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 5.36 12/31/22 - 5.65 09/30/22 - 5.92 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©